
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Ischemia Reperfusion Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 35 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.
Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Ischemia Reperfusion Injury (Cardiovascular) pipeline landscape.
Ischemic reperfusion injury is the tissue damage that happens when blood supply returns to the tissue after a period of lack of oxygen. The absence of oxygen and nutrients creates a condition in which the restoration of circulation results in inflammation and oxidative damage through the induction of oxidative. Symptoms include headache, bradycardia, seizures and hypertension. Risk factors include hypertension, hyperlipidemia, diabetes, insulin resistance, heart failure, altered coronary circulation, and aging.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ischemia Reperfusion Injury - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Ischemia Reperfusion Injury (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Ischemia Reperfusion Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 6, 35 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 16 and 1 molecules, respectively.
Ischemia Reperfusion Injury (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ischemia Reperfusion Injury (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ischemia Reperfusion Injury (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ischemia Reperfusion Injury (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ischemia Reperfusion Injury (Cardiovascular)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ischemia Reperfusion Injury (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ischemia Reperfusion Injury (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Companies Mentioned
Abfero Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Apollo Therapeutics LLC
Argenx SE
Asta Pharmaceuticals Co Ltd
Axolo Pharma Inc
Balmes Transplantation SAS
Beijing Northland Biotech Co Ltd
Bolder Biotechnology Inc
Celdara Medical LLC
CFM Pharma Holding BV
Corline Biomedical AB
Curacle Co Ltd
Cypralis Ltd
Domainex Ltd
EVAS Therapeutics LLC
Faron Pharmaceuticals Oy
Gero Discovery
Gilead Sciences Inc
Glucox Biotech AB
Ischemix Inc
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
LUCA Science Inc
Mallinckrodt Plc
Neuroene Therapeutics LLC
New Beta Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Orion Corp
Oxitope Pharma BV
Pfizer Inc
Pharming Group NV
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Revive Therapeutics Ltd
Sairiyo Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Slate Bio Inc
Stealth BioTherapeutics Corp
TheraSource LLC
United Therapeutics Corp
Young Therapeutics LLC
Companies Mentioned
Abfero Pharmaceuticals Inc
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Apollo Therapeutics LLC
Argenx SE
Asta Pharmaceuticals Co Ltd
Axolo Pharma Inc
Balmes Transplantation SAS
Beijing Northland Biotech Co Ltd
Bolder Biotechnology Inc
Celdara Medical LLC
CFM Pharma Holding BV
Corline Biomedical AB
Curacle Co Ltd
Cypralis Ltd
Domainex Ltd
EVAS Therapeutics LLC
Faron Pharmaceuticals Oy
Gero Discovery
Gilead Sciences Inc
Glucox Biotech AB
Ischemix Inc
Larix Bioscience LLC
Lee's Pharmaceutical Holdings Ltd
LUCA Science Inc
Mallinckrodt Plc
Neuroene Therapeutics LLC
New Beta Innovation Ltd
New Horizons Pharma Inc
Nour Heart Therapeutics LLC
NuNerve Pty Ltd
Orion Corp
Oxitope Pharma BV
Pfizer Inc
Pharming Group NV
Radikal Therapeutics Inc
Reata Pharmaceuticals Inc
Revive Therapeutics Ltd
Sairiyo Therapeutics Inc
SBI Pharmaceuticals Co Ltd
Slate Bio Inc
Stealth BioTherapeutics Corp
TheraSource LLC
United Therapeutics Corp
Young Therapeutics LLC
Table of Contents
141 Pages
- Introduction
- Global Markets Direct Report Coverage
- Ischemia Reperfusion Injury - Overview
- Ischemia Reperfusion Injury - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ischemia Reperfusion Injury - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ischemia Reperfusion Injury - Companies Involved in Therapeutics Development
- Abfero Pharmaceuticals Inc
- Amyndas Pharmaceuticals LLC
- Anagenics Ltd
- Apollo Therapeutics LLC
- Argenx SE
- Asta Pharmaceuticals Co Ltd
- Axolo Pharma Inc
- Balmes Transplantation SAS
- Beijing Northland Biotech Co Ltd
- Bolder Biotechnology Inc
- Celdara Medical LLC
- CFM Pharma Holding BV
- Corline Biomedical AB
- Curacle Co Ltd
- Cypralis Ltd
- Domainex Ltd
- EVAS Therapeutics LLC
- Faron Pharmaceuticals Oy
- Gero Discovery
- Gilead Sciences Inc
- Glucox Biotech AB
- Ischemix Inc
- Larix Bioscience LLC
- Lee's Pharmaceutical Holdings Ltd
- LUCA Science Inc
- Mallinckrodt Plc
- Neuroene Therapeutics LLC
- New Beta Innovation Ltd
- New Horizons Pharma Inc
- Nour Heart Therapeutics LLC
- NuNerve Pty Ltd
- Orion Corp
- Oxitope Pharma BV
- Pfizer Inc
- Pharming Group NV
- Radikal Therapeutics Inc
- Reata Pharmaceuticals Inc
- Revive Therapeutics Ltd
- Sairiyo Therapeutics Inc
- SBI Pharmaceuticals Co Ltd
- Slate Bio Inc
- Stealth BioTherapeutics Corp
- TheraSource LLC
- United Therapeutics Corp
- Young Therapeutics LLC
- Ischemia Reperfusion Injury - Drug Profiles
- aminolevulinic acid hydrochloride - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ANV-6L15 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AP-39 - Drug Profile
- Product Description
- Mechanism Of Action
- APP-103 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ARGX-117 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- AZ-67 - Drug Profile
- Product Description
- Mechanism Of Action
- BBT-059 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Biologic for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- BT-0213 - Drug Profile
- Product Description
- Mechanism Of Action
- BT-0301 - Drug Profile
- Product Description
- Mechanism Of Action
- BT-0402 - Drug Profile
- Product Description
- Mechanism Of Action
- bucillamine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CAB-101 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- cannabidiol - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CC-4066 - Drug Profile
- Product Description
- Mechanism Of Action
- cerium oxide - Drug Profile
- Product Description
- Mechanism Of Action
- CMX-2043 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- conestat alfa - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- CU-103 - Drug Profile
- Product Description
- Mechanism Of Action
- cyclocreatine phosphate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DH-404 - Drug Profile
- Product Description
- Mechanism Of Action
- dimethyltryptamine - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- DMX-5804 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Drugs for Ischemia Reperfusion Injuries - Drug Profile
- Product Description
- Mechanism Of Action
- FAX-051T - Drug Profile
- Product Description
- Mechanism Of Action
- Fusion Protein to Antagonize EPHA4 for CNS Disorders, Cardiovascular Diseases and Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- HUB-1023 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- IL-233 - Drug Profile
- Product Description
- Mechanism Of Action
- interferon beta-1a - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- KN-93 - Drug Profile
- Product Description
- Mechanism Of Action
- M-3mP6 - Drug Profile
- Product Description
- Mechanism Of Action
- MG-53 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MitoDak - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibodies to Inhibit MMP-8 for Ischemia Reperfusion Injury and Shock - Drug Profile
- Product Description
- Mechanism Of Action
- Monoclonal Antibody for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Monoclonal Antibody to Inhibit IL-16 for Ischemia Reperfusion Injury and Inflammation - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- MP-3964 - Drug Profile
- Product Description
- Mechanism Of Action
- Oligonucleotide for Cardiovascular Diseases and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- ORM-10103 - Drug Profile
- Product Description
- Mechanism Of Action
- Peptides to Modulate SRC Family Kinase for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- R-100 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- R-190 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Enzymes to Activate ALDH2 for Alcohol Poisoning, Ischemia Reperfusion Injury and Metabolic Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury and Sepsis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Recombinant Protein to Agonize Robo1 for Ischemia Reperfusion Injury and Thrombosis - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Proteins for Ischemia Reperfusion Injury and Hypoxia - Drug Profile
- Product Description
- Mechanism Of Action
- Recombinant Proteins to Agonize PTCH1 for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- regadenoson - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Remodulin - Drug Profile
- Product Description
- Mechanism Of Action
- Renaparin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SBT-272 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Ischemia Reperfusion Injury and Neuroinflammation - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules for Metastatic Liver Cancer and Hepatic Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Activate Protein Kinase B for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit CRP for Ischemic Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Inhibit NOX4 and NOX2 for Ischemia Reperfusion Injury - Drug Profile
- Product Description
- Mechanism Of Action
- SP-420 - Drug Profile
- Product Description
- Mechanism Of Action
- Synthetic Peptides for Cardiovascular Disorders, Immunology and Oncology - Drug Profile
- Product Description
- Mechanism Of Action
- tiomolibdate diammonium - Drug Profile
- Product Description
- Mechanism Of Action
- tofacitinib citrate - Drug Profile
- Product Description
- Mechanism Of Action
- UWA-TAT - Drug Profile
- Product Description
- Mechanism Of Action
- Vanadis-01 - Drug Profile
- Product Description
- Mechanism Of Action
- Vanadis-03 - Drug Profile
- Product Description
- Mechanism Of Action
- VCP-746 - Drug Profile
- Product Description
- Mechanism Of Action
- YQ-23 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- YT-001 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- YT-002 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- YT-004 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- ZK-001 - Drug Profile
- Product Description
- Mechanism Of Action
- Ischemia Reperfusion Injury - Dormant Projects
- Ischemia Reperfusion Injury - Discontinued Products
- Ischemia Reperfusion Injury - Product Development Milestones
- Featured News & Press Releases
- Feb 15, 2022: Revive Therapeutics receives FDA Orphan Drug Designation for Bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation
- Jan 17, 2022: Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson injection, 0.4 mg/5 mL (0.08 mg/mL) single-dose pre-filled syringe
- Nov 23, 2021: Revive Therapeutics files for FDA Orphan Drug Designation for bucillamine in the prevention of ischemia-reperfusion injury during liver transplantation
- Jun 19, 2021: Recombinant Human Thymosin ß4 for Injection Phase IIa Clinical Trial Interim Investigator Meeting Successfully Held
- Jan 20, 2020: Revive Therapeutics provides update on its cannabinoid program initiatives for drug delivery and in the prevention of ischemia and reperfusion injury from organ transplantation
- May 05, 2019: Clinical trial shows promise for increasing lung transplant patients life expectancy
- Aug 22, 2018: Revive Therapeutics applies to FDA For Orphan Drug Designation of Cannabidiol for treatment of Liver Transplantation
- Jun 12, 2018: Corline Biomedical: Application for clinical trial of Renaparin submitted
- Mar 26, 2018: UVA Launches Human Tests of Lung Transplant Drug
- Aug 03, 2017: Corline Biomedical: Notice of allowance for Renaparin patent in the United States
- May 04, 2017: Corline receives orphan drug status in the United States
- Jan 27, 2017: Notice on the Start of Phase II Clinical Trial using 5-ALA by University of Oxford and SBI Pharmaceuticals
- Dec 09, 2015: Ischemix Announces First International Patent Coverage of Novel Analogs of its Lead Cytoprotective Compound
- Sep 30, 2015: Ischemix Completes Enrollment of Phase 2 Trial for Prevention of Acute Kidney Injury and Cardiac Injury in Cardiac Catheterization Patients
- Jul 02, 2012: Pharming Announces Publication Of New Data On Ruconest’s Protective Effects After Severe Blood Loss In Journal Shock
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products under Development for Ischemia Reperfusion Injury, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Companies, 2022 (Contd..1)
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Products under Development by Companies, 2022 (Contd..2)
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Target, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Ischemia Reperfusion Injury - Pipeline by Abfero Pharmaceuticals Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Amyndas Pharmaceuticals LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by Anagenics Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Apollo Therapeutics LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by Argenx SE, 2022
- Ischemia Reperfusion Injury - Pipeline by Asta Pharmaceuticals Co Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Axolo Pharma Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Balmes Transplantation SAS, 2022
- Ischemia Reperfusion Injury - Pipeline by Beijing Northland Biotech Co Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Bolder Biotechnology Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Celdara Medical LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by CFM Pharma Holding BV, 2022
- Ischemia Reperfusion Injury - Pipeline by Corline Biomedical AB, 2022
- Ischemia Reperfusion Injury - Pipeline by Curacle Co Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Cypralis Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Domainex Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by EVAS Therapeutics LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by Faron Pharmaceuticals Oy, 2022
- Ischemia Reperfusion Injury - Pipeline by Gero Discovery, 2022
- Ischemia Reperfusion Injury - Pipeline by Gilead Sciences Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Glucox Biotech AB, 2022
- Ischemia Reperfusion Injury - Pipeline by Ischemix Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Larix Bioscience LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by LUCA Science Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Mallinckrodt Plc, 2022
- Ischemia Reperfusion Injury - Pipeline by Neuroene Therapeutics LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by New Beta Innovation Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by New Horizons Pharma Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Nour Heart Therapeutics LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by NuNerve Pty Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Orion Corp, 2022
- Ischemia Reperfusion Injury - Pipeline by Oxitope Pharma BV, 2022
- Ischemia Reperfusion Injury - Pipeline by Pfizer Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Pharming Group NV, 2022
- Ischemia Reperfusion Injury - Pipeline by Radikal Therapeutics Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Reata Pharmaceuticals Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Revive Therapeutics Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Sairiyo Therapeutics Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by SBI Pharmaceuticals Co Ltd, 2022
- Ischemia Reperfusion Injury - Pipeline by Slate Bio Inc, 2022
- Ischemia Reperfusion Injury - Pipeline by Stealth BioTherapeutics Corp, 2022
- Ischemia Reperfusion Injury - Pipeline by TheraSource LLC, 2022
- Ischemia Reperfusion Injury - Pipeline by United Therapeutics Corp, 2022
- Ischemia Reperfusion Injury - Pipeline by Young Therapeutics LLC, 2022
- Ischemia Reperfusion Injury - Dormant Projects, 2022
- Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..1)
- Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..2)
- Ischemia Reperfusion Injury - Dormant Projects, 2022 (Contd..3)
- Ischemia Reperfusion Injury - Discontinued Products, 2022
- List of Figures
- Number of Products under Development for Ischemia Reperfusion Injury, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.